Kurtz Ronald M MD
Known title: President & CEOCIK: 0001295469
Associated companies
Transaction History
| RXST | ▼ Sell | Open Market | 5,100 | $35K | 9/2/2026 | View on chart |
| RXST | ▲ Buy | Option Exercise | 13,425 | — | 8/31/2026 | View on chart |
| RXST | ▲ Buy | Option Exercise | 7,650 | $115K | 8/9/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 2,300 | $10K | 8/9/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 13,500 | $204K | 7/11/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 40,000 | $2.4M | 5/3/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 31,250 | $1.4M | 1/8/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 31,250 | $1.4M | 1/8/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 22,500 | $924K | 12/27/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 20,000 | $800K | 12/14/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 20,000 | $788K | 12/14/2023 | View on chart |
| RXST | ▲ Buy | Grant | 40,000 | $500K | 2/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.